Intestinal epithelial cells express immunomodulatory ISG15 during active ulcerative colitis and Crohn's disease
Permanent link
https://hdl.handle.net/10037/20231Date
2020-02-05Type
Journal articleTidsskriftartikkel
Peer reviewed
Author
Østvik, Ann Elisabet; Svendsen, Tarjei Dahl; Granlund, Atle van Beelen; Doseth, Berit; Skovdahl, Helene Kolstad; Bakke, Ingunn; Thorsvik, Silje; Afroz, Wahida; Walaas, Gunnar Andreas; Mollnes, Tom Eirik; Gustafsson, Björn; Sandvik, Arne Kristian; Bruland, TorunnAbstract
Methods - Gene and protein expression in whole mucosa biopsies and in microdissected human colonic epithelial lining, in HT29 human intestinal epithelial cells and primary 3D colonoids treated with PRR-ligands and cytokines, were detected by transcriptomics, in situ hybridisation, immunohistochemistry, western blots, and enzyme-linked immunosorbent assay [ELISA]. Effects of IEC-secreted cytokines were examined in human peripheral blood mononuclear cells [PBMCs] by multiplex chemokine profiling and ELISA.
Results - The type I IFN gene signature in human mucosal biopsies was mimicked in Toll-like receptor TLR3 and to some extent tumour necrosis factor [TNF]-treated human IECs. In intestinal biopsies, ISG15 expression correlated with expression of the newly identified receptor for extracellular ISG15, LFA-1 integrin. ISG15 was expressed and secreted from HT29 cells and primary 3D colonoids through both JAK1-pSTAT-IRF9-dependent and independent pathways. In experiments using PBMCs, we show that ISG15 releases IBD-relevant proinflammatory cytokines such as CXCL1, CXCL5, CXCL8, CCL20, IL1, IL6, TNF, and IFNγ.
Conclusions - ISG15 is secreted from primary IECs upon extracellular stimulation, and mucosal ISG15 emerges as an intriguing candidate for immunotherapy in IBD.